SEMA4C and breast cancer: Future therapeutics aimed at blocking PLXNB2 and SEMA4C/4A interactions can potentially serve as targeting strategies in breast cancer, especially TNBC and complement existing treatments, such as pembrolizumab69–71, Sacituzumab72,73, and Palbociclib74 for improved outcomes.